Biocardia Stock Investor Sentiment
| BCDA Stock | USD 2.60 0.03 1.17% |
About 68 percent of all Biocardia's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Biocardia suggests that a large number of traders are confidant. The current market sentiment, together with Biocardia's historical and current headlines, can help investors time the market. In addition, many technical investors use Biocardia stock news signals to limit their universe of possible portfolio assets.
Biocardia |
Biocardia Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Biocardia can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Biocardia that are available to investors today. That information is available publicly through Biocardia media outlets and privately through word of mouth or via Biocardia internal channels. However, regardless of the origin, that massive amount of Biocardia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biocardia news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biocardia relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biocardia's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biocardia alpha.
Biocardia Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 3257 shares by Edward Gillis of Biocardia at 2.0 subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Peter Altman of 1000 shares of Biocardia at 2.06 subject to Rule 16b-3 | 12/23/2024 |
3 | Biocardia senior vice president Edward Gillis sells 6,514 in stock - Investing.com | 12/26/2024 |
4 | BioCardia, Inc. Short Interest Down .6 percent in December | 01/17/2025 |
5 | Acquisition by Peter Altman of 500 shares of Biocardia at 2.4 subject to Rule 16b-3 | 01/29/2025 |
6 | Acquisition by Peter Altman of 2 shares of Biocardia at 2.38 subject to Rule 16b-3 | 01/30/2025 |
7 | 12 Health Care Stocks Moving In Mondays Pre-Market Session - Benzinga | 02/03/2025 |
8 | Acquisition by Peter Altman of 600 shares of Biocardia at 2.48 subject to Rule 16b-3 | 02/07/2025 |
9 | Biocardia CEO Peter Altman acquires 1,488 in stock - Investing.com | 02/11/2025 |
10 | Acquisition by Peter Altman of 500 shares of Biocardia at 2.11 subject to Rule 16b-3 | 03/03/2025 |
11 | BioCardia, Inc. Director Simon H. Stertzer Acquires 22,753 Shares | 03/05/2025 |
12 | Reviewing BioCardia Moderna - Defense World | 03/12/2025 |
Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |